Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Caligan Partners LP

Caligan Partners LP lessened its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 42.7% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 184,826 shares of the biotechnology company's stock after selling 137,627 shares during the period. Enanta Pharmaceuticals comprises approximately 0.3% of Caligan Partners LP's investment portfolio, making the stock its 14th largest holding. Caligan Partners LP owned 0.87% of Enanta Pharmaceuticals worth $1,063,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. increased its stake in Enanta Pharmaceuticals by 53.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company's stock worth $2,524,000 after acquiring an additional 85,082 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Enanta Pharmaceuticals by 34.1% in the fourth quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company's stock valued at $1,109,000 after acquiring an additional 49,050 shares during the last quarter. Barclays PLC grew its holdings in Enanta Pharmaceuticals by 294.2% during the 3rd quarter. Barclays PLC now owns 27,438 shares of the biotechnology company's stock worth $285,000 after acquiring an additional 20,478 shares during the period. Geode Capital Management LLC lifted its stake in Enanta Pharmaceuticals by 3.1% in the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company's stock valued at $4,946,000 after buying an additional 14,575 shares during the period. Finally, AlphaQuest LLC lifted its position in shares of Enanta Pharmaceuticals by 16.4% during the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 3,137 shares during the period. 94.99% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on ENTA. HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. JMP Securities reiterated a "market outperform" rating and set a $21.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Finally, StockNews.com upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Enanta Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $17.25.

Insider Transactions at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly purchased 45,000 shares of the stock in a transaction that occurred on Wednesday, February 12th. The stock was bought at an average cost of $5.69 per share, for a total transaction of $256,050.00. Following the completion of the transaction, the chief executive officer now directly owns 846,638 shares in the company, valued at $4,817,370.22. This represents a 5.61 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 13.89% of the company's stock.

Enanta Pharmaceuticals Stock Performance

Shares of ENTA traded down $0.36 during mid-day trading on Tuesday, reaching $5.09. The company had a trading volume of 143,466 shares, compared to its average volume of 286,070. Enanta Pharmaceuticals, Inc. has a 52 week low of $4.09 and a 52 week high of $17.24. The firm has a 50-day moving average price of $5.86 and a 200 day moving average price of $7.01. The company has a market capitalization of $108.48 million, a price-to-earnings ratio of -1.03 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last issued its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, research analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current fiscal year.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.